Study of Ataluren (PTC124™) in Cystic Fibrosis

This study has been completed.
Sponsor:
Collaborator:
Cystic Fibrosis Foundation
Information provided by (Responsible Party):
PTC Therapeutics
ClinicalTrials.gov Identifier:
NCT00803205
First received: December 4, 2008
Last updated: August 14, 2013
Last verified: August 2013

December 4, 2008
August 14, 2013
July 2009
November 2011   (final data collection date for primary outcome measure)
Forced expiratory volume in 1 second (FEV1) [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00803205 on ClinicalTrials.gov Archive Site
  • Pulmonary exacerbation frequency [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
  • Cough frequency [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
  • Respiratory HRQL as assessed by the CFQ-R respiratory domain [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
  • Forced vital capacity (FVC) [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
  • Safety profile [ Time Frame: 48 weeks ] [ Designated as safety issue: Yes ]
  • Compliance with study drug administration [ Time Frame: 48 weeks ] [ Designated as safety issue: Yes ]
  • Ataluren (PTC124) pharmacokinetics [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
  • Antibiotic use and hospitalization due to CF-related symptoms [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
  • Disruptions to school or work due to CF-related symptoms [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
  • Body weight [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
  • Markers of lung inflammation [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
  • Lung computerized tomography CF score [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
  • Nasal transepithelial potential difference (TEPD) [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
  • Sweat chloride concentration [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
  • Pulmonary exacerbation frequency [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
  • Cough frequency [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
  • Respiratory HRQL as assessed by the CFQ-R respiratory domain [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
  • Forced vital capacity (FVC) [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
  • Safety profile [ Time Frame: 48 weeks ] [ Designated as safety issue: Yes ]
  • Compliance with study drug administration [ Time Frame: 48 weeks ] [ Designated as safety issue: Yes ]
  • PTC124 pharmacokinetics [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
  • Antibiotic use and hospitalization due to CF-related symptoms [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
  • Disruptions to school or work due to CF-related symptoms [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
  • Body weight [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
  • Markers of lung inflammation [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
  • Lung computerized tomography CF score [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
  • Nasal transepithelial potential difference (TEPD) [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
  • Sweat chloride concentration [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Study of Ataluren (PTC124™) in Cystic Fibrosis
A Phase 3 Efficacy and Safety Study of PTC124 as an Oral Treatment for Nonsense-Mutation-Mediated Cystic Fibrosis

Cystic fibrosis (CF) is a genetic disorder caused by a mutation in the gene that makes the cystic fibrosis transmembrane conductance regulator (CFTR) protein. A specific type of mutation called a nonsense (premature stop codon) mutation is the cause of CF in approximately 10% of subjects with the disease. Ataluren (PTC124) is an orally delivered investigational drug that has the potential to overcome the effects of the nonsense mutation. This study is a Phase 3 trial that will evaluate the clinical benefit of ataluren (PTC124) in adult and pediatric patients with CF due to a nonsense mutation. The main goals of the study are to understand whether ataluren (PTC124) can improve pulmonary function and whether the drug can safely be given for a long period of time. The study will also assess the effects of ataluren on CF pulmonary exacerbation frequency, cough frequency, health-related quality of life, antibiotic use for CF-related infections, CF-related disruptions to daily living, body weight, and CF pathophysiology. Funding Source - FDA OOPD

This study is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, efficacy and safety study, designed to document the clinical benefit of ataluren (PTC124) when administered as therapy of patients with CF due to a nonsense mutation (premature stop codon) in the CFTR gene. It is planned that ~208 subjects who are ≥6 years of age and have an FEV1 ≥40% and ≤90% of predicted will be enrolled. Study subjects will be enrolled at sites in North America, Europe, and Israel. They will be randomized in a 1:1 ratio to either ataluren (PTC124) or placebo. Subjects will receive study drug 3 times per day (at morning, midday, and evening) for 48 weeks. Subjects will be evaluated at clinic visits every 8 weeks. Additional safety laboratory testing, which may be performed at the investigational site or at an accredited local laboratory or clinic, is required every 4 weeks for the first 6 months of study participation. At the completion of blinded treatment, all compliant participants will be eligible to receive open-label ataluren (PTC124) in a separate extension study.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Cystic Fibrosis
  • Drug: Ataluren (PTC124)
    10-, 10-, 20-mg/kg TID at morning, midday, and evening doses
    Other Name: PTC124
  • Drug: Placebo
    Placebo
  • Experimental: Ataluren (PTC124)
    Intervention: Drug: Ataluren (PTC124)
  • Placebo Comparator: Placebo
    Intervention: Drug: Placebo
Kerem E, Konstan MW, De Boeck K, Accurso FJ, Sermet-Gaudelus I, Wilschanski M, Elborn JS, Melotti P, Bronsveld I, Fajac I, Malfroot A, Rosenbluth DB, Walker PA, McColley SA, Knoop C, Quattrucci S, Rietschel E, Zeitlin PL, Barth J, Elfring GL, Welch EM, Branstrom A, Spiegel RJ, Peltz SW, Ajayi T, Rowe SM; Cystic Fibrosis Ataluren Study Group. Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respir Med. 2014 Jul;2(7):539-47. doi: 10.1016/S2213-2600(14)70100-6. Epub 2014 May 15.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
238
October 2012
November 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Ability to provide written informed consent (parental/guardian consent and subject assent if <18 years of age)
  • Age ≥6 years
  • Body weight ≥16 kg
  • Abnormal nasal TEPD total chloride conductance (a less electrically negative value than -5 mV for total chloride conductance [Δchloride-free+isoproterenol])
  • Sweat chloride >40 mEq/L
  • Documentation of the simultaneous presence of a nonsense mutation in at least 1 allele of the CFTR gene and a CF-causing mutation in the other CFTR allele, as determined by gene sequencing from a laboratory certified by the College of American Pathologists (CAP), or under the Clinical Laboratory Improvement Act/Amendment (CLIA), or by an equivalent organization
  • Verification that a blood sample has been drawn for confirmation of the presence of a nonsense mutation in the CFTR gene
  • Ability to perform a valid, reproducible spirometry test using the study-specific spirometer with demonstration of an FEV1 ≥40% and ≤90% of predicted for age, gender, and height
  • Resting oxygen saturation (as measured by pulse oximetry) ≥92% on room air
  • Documentation by VivoMetrics that the subject has satisfactorily completed a 24-hour LifeShirt® cough frequency assessment
  • Confirmed screening laboratory values within the central laboratory ranges (hepatic, adrenal, renal, serum electrolytes, and reproduction [women only] parameters)
  • In subjects who are sexually active, willingness to abstain from sexual intercourse or employ a barrier or medical method of contraception during the study drug administration and 4-week follow-up period
  • Willingness and ability to comply with scheduled visits, drug administration plan, study restrictions, and study procedures

Exclusion Criteria:

  • Known hypersensitivity to any of the ingredients or excipients of the study drug
  • Any change (initiation, change in type of drug, dose modification, schedule modification, interruption, discontinuation, or reinitiation) in a chronic treatment/prophylaxis regimen for CF or for CF-related conditions within 4 weeks prior to start of study treatment
  • Exposure to another investigational drug within 4 weeks prior to start of study treatment
  • Treatment with systemic aminoglycoside antibiotics at the time of the baseline TEPD assessment
  • Treatment with intravenous antibiotics within 3 weeks prior to start of study treatment
  • History of solid organ or hematological transplantation
  • Ongoing immunosuppressive therapy (other than corticosteroids)
  • Ongoing warfarin, phenytoin, or tolbutamide therapy
  • Ongoing participation in any other therapeutic clinical trial
  • Major complications of lung disease (including massive hemoptysis, pneumothorax, or pleural effusion) within 8 weeks prior to start of study treatment
  • Evidence of pulmonary exacerbation or acute upper or lower respiratory tract infection (including viral illnesses) within 3 weeks prior to randomization
  • Known portal hypertension
  • Positive hepatitis B surface antigen, hepatitis C antibody test, or human immunodeficiency virus (HIV) test
  • Pregnancy or breast-feeding
  • Current smoker or a smoking history of ≥10 pack-years (number of cigarette packs/day x number of years smoked)
  • Prior or ongoing medical condition (eg, concomitant illness, alcoholism, drug abuse, psychiatric condition), medical history, physical findings, ECG findings, or laboratory abnormality that, in the investigator's opinion, could adversely affect the safety of the subject, makes it unlikely that the course of treatment or follow-up would be completed, or could impair the assessment of study results
Both
6 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United Kingdom,   Italy,   United States,   Israel,   Spain,   France,   Belgium,   Sweden,   Germany,   Netherlands,   Canada
 
NCT00803205
PTC124-GD-009-CF, Orphan Product Grant #FD003715
Yes
PTC Therapeutics
PTC Therapeutics
Cystic Fibrosis Foundation
Study Director: Temitayo Ajayi, MD PTC Therapeutics
PTC Therapeutics
August 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP